Biotech & Pharma

Novo to cut GLP-1 drug prices; Palvella soars on study data

24 sec read7 views0 listens

Novo Nordisk announced a up to 50% price cut for Wegovy and Ozempic starting next year; Palvella's stock soared above $1 billion after positive study data. These changes significantly impact the market dynamics for obesity drugs, offering more affordable options to consumers while highlighting the competitive landscape for pharmaceutical companies in this sector.

Read the full article at BioPharma Dive

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Gaming11 hours ago25 sec read

In GTA 6 You're Not Just Wanted, You're Hunted

Rockstar Games has reintroduced the full six-star wanted system in Grand Theft Auto 6, adding new layers to the police chase mechanics with a heat system that tracks players' appearances and actions through multiple data points. This enhancement incr...

Ali Nemati

Ecommerce Retail12 hours ago27 sec read

Cab Clutter Can Cost Fleets Millions

Professional truck driver James Boyce has developed Trucker Tote, a modular cab organizer aimed at reducing distracted driving and potential legal liabilities for fleets. With fatality verdicts in commercial trucking averaging $7 million per case and...

Ali Nemati

Tech & Gadgets20 hours ago27 sec read

Sovereignty is now a feature, and Canadian founders are shipping it for free

Canadian startups are increasingly offering data sovereignty as a key selling point in response to heightened concerns over vendor nationality and data security. This shift reflects growing demand from buyers seeking to mitigate geopolitical risks, w...

Ali Nemati